Clinical Trial

A Study to Evaluate the Effect of Fasting Duration and Tirzepatide Withholding on the Amount of Food and Fluid in the Stomach in Participants With Type 2 Diabetes Mellitus and Participants With Overweight or Obesity Without Type 2 Diabetes Mellitus

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The purpose of this study is to evaluate how fasting and stopping the use of tirzepatide affects the amount of food and drink that stays in the stomach after a meal. Ultrasound will be used to check the stomach content after a test meal.
Protocol Amendment History 3 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-20
notable Primary completion pushed: 2026-10 -> 2026-11 2026-04-17
minor Completion pushed: 2026-10 -> 2026-11 2026-04-17
Trial Details
NCT Number NCT07299084
Lead Sponsor Eli Lilly and Company
Conditions Diabetes Mellitus, Type 2, Overweight, Obesity
Enrollment 40 participants
Start Date 2026-01-14
Primary Completion 2026-11 (estimated)
Study Completion 2026-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-19